Divalproex Sodium
Product Images NDC 17856-0798

This is a description for a medication called Divalproex Sodium that comes in the form of 500 mg delayed-release tablets. The medicine is only available with a prescription and should be kept away from children. The packaging information includes one tablet per unit dose and 100 tables per case. The medication should be stored at 20° to 25°C (66° to 77°F) and excursions are permitted at 10 to 15°C (59° to 86°F). The manufacturer is Sun Pharmaceuticals Industries Ltd. The drug's repackaging is done by Unit Dose Solutors, Inc. and distributed by Atlantic Biologicals Corp. The lot and manufacturing details are also provided, and the package insert should be read for indications and dosage schedule. For any queries or comments, one can call the given phone number.*

This text appears to be a figure caption from a research study, with references to two different studies labeled Study 1 and Study 2. The treatments under investigation are identified as PBO and DVPX, but without additional context it is unclear what these abbreviations represent. The studies utilize two different rating scales, labeled YMRS and MRS. Without further information, it is difficult to provide a more specific description or interpretation of the data presented in this figure.*

This text appears to be a graph or chart with a comparison between two groups (DVPX and Placebo) in terms of reduction in CPS (Central Pain Syndrome) rate. The graph shows percentages ranging from -100% to 100% with a scale of 25% in between. The x-axis shows the percentage of patients and the y-axis shows the level of improvement, no change or worsening.*

The text describes a figure labeled "Figure 4" that shows the mean 4-week migraine rates for two different treatments: "Placebo" and "DVPX". There are two studies represented in the figure labeled "Study 1" and "Study 2". However, there is not enough context to fully understand the significance of the data or the purpose of the figure.*